Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Checkpoint Kinase Inhibitor AZD7762

A synthetic small molecule inhibitor of checkpoint kinases (Chks) with potential chemosensitizing activity. AZD7762 binds to and inhibits Chks, which… Expand
National Institutes of Health

Related topics

Related topics

1 relation
AZD 7762

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Redirecting extracellular proteases to molecularly guide radiosensitizing drugs to tumors.
Patients with advanced cancers are treated with combined radiotherapy and chemotherapy, however curability is poor and treatment… Expand
Is this relevant?
2019
2019
Checkpoint kinase inhibitor AZD7762 enhance cisplatin-induced apoptosis in osteosarcoma cells
BackgroundAZD7762 is a checkpoint kinase 1 (Chk 1) inhibitor, which has been reported to sensitize many tumor cells to DNA damage… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2018
2018
Enhancing Abiraterone Acetate Efficacy in Androgen Receptor–positive Triple-negative Breast Cancer: Chk1 as a Potential Target
Purpose: Our aim was to identify predictive factors of abiraterone acetate efficacy and putative new druggable targets in… Expand
  • table 1
  • table 2
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
2017
2017
Checkpoint kinase inhibitor AZD7762 strongly sensitises urothelial carcinoma cells to gemcitabine
BackgroundMore effective chemotherapies are urgently needed for bladder cancer, a major cause of morbidity and mortality… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2014
2014
Checkpoint Kinase Inhibitor AZD7762 Overcomes Cisplatin Resistance in Clear Cell Carcinoma of the Ovary
Objective Checkpoint kinase (Chk) inhibitors are thought to increase the cytotoxic effects of DNA-damaging agents and are… Expand
Is this relevant?
2012
2012
The Checkpoint Kinase Inhibitor AZD7762 Potentiates Chemotherapy-Induced Apoptosis of p53-Mutated Multiple Myeloma Cells
DNA cross-linking agents are frequently used in the treatment of multiple myeloma–generating lesions, which activate checkpoint… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE